

Estimate changes 

TP change 

Rating change 

Bloomberg	SAGILITY IN
Equity Shares (m)	4681
M.Cap.(INRM)/(USDM)	201.7 / 2.1
52-Week Range (INR)	58 / 36
1, 6, 12 Rel. Per (%)	5/-7/7
12M Avg Val (INR M)	1923

Financials Snapshot (INR m)

Y/E MARCH	FY26	FY27E	FY28E
Sales	71,929	82,634	93,976
Sales Gr. (%)	29.1	14.9	13.7
EBITDA	17,570	20,121	22,604
EBITDA Margin (%)	24.4	24.3	24.1
Reported PAT	9,248	10,957	13,405
EPS (Rs)	1.98	2.34	2.86
EPS Gr. (%)	68.9	18.5	22.3
BV/Share	20.6	22.7	25.3
Ratios			
RoE	10.3	10.8	11.9
RoCE	12.4	13.5	14.6
RoIC	10.1	11.3	13.0

Valuations

EV/Sales	2.9	2.4	2.0
EV/EBITDA	11.9	9.7	8.4
P/E (X)	21.8	18.4	15.0
P/BV (X)	2.1	1.9	1.7

Shareholding pattern (%)

As On	Mar-26	Dec-25	Mar-25
Promoter	51.0	51.0	82.4
FII	22.3	21.4	7.5
DII	10.0	10.3	3.4
Others	16.7	17.4	6.7

CMP: INR43

TP: INR57 (+32%)

Buy

Strong FY26; FY27 to be a year of normalization

- Sagility's 4QFY26 revenue rose 25.8% YoY in constant currency (CC), in line with expectations. EBIT margin stood at 17.8%, and adj. PAT came in at INR3.1b (up 28.0% YoY), below our estimate of INR3.3b due to a higher tax rate and margin-related impact.
- During FY26, Sagility's revenue/EBITDA/adj. PAT grew 29.1%/35.4%/39.5% YoY in INR terms. Management guided for low double-digit CC revenue growth in FY27 and EBITDA margin of 24-25%. Margins are expected to trend toward the upper end of the range. We value the stock at 20x FY28E EPS to arrive at our TP of INR57. **We reiterate our BUY rating on the stock.**

Our view: US healthcare cost pressure remains a structural tailwind

- **Healthy FY26 growth; FY27 to be a normal year:** Sagility posted 23.6% YoY CC growth in FY26 on the back of continued expansion within existing clients and increasing contribution from new clients acquired in FY26.
- We estimate revenue growth of ~11.4% YoY CC in FY27 and EBITDA margin of 24.3% in FY27 and expect growth to accelerate in FY28.
- **Margin to remain range-bound:** EBITDA margin at 25.9% was within the guided range. Focusing on outcome-based engagements helps de-link revenue from transaction- or headcount-based pricing, thus improving margin resilience. However, we do not expect any meaningful margin expansion in the near term, given the pricing and cost pressure faced by the US-based health insurance companies. Overall, we expect margins to remain range-bound and model a ~24-25% EBITDA margin for FY27-28, considering likely margin risk.
- **Deal TCV:** Commercial momentum remained healthy, with USD30.7m of potential steady-state ACV signed during 4QFY26 through expansion and new statements of work across 18 existing clients and clients added during FY26. Full-year ACV wins were ~USD130m.
- Client concentration is continuously improving, with the top three clients now contributing less than 60% of revenue, while the number of clients generating more than USD20m annually increased to nine in FY26 from four in FY23.

Valuation and View:

We believe FY27 will be a year of growth normalization considering a high base of FY26. We expect business to grow in normalized lower double digits and margin to remain in the current range only. We believe the new logo addition, cross-selling, and synergy from Broadpath will drive its revenue/EBITDA/PAT CAGR of 19%/20%/24% over FY25-28. Consequently, **we reiterate our BUY rating** on the stock with a TP of INR57 (based on 20x on FY28E EPS).

Quarterly Earnings Model

(INR m)

Y/E March	FY25				FY26E				FY25	FY26	Est. FY26E	Var. (% / bp)
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q				
Revenue (USD m)	148	158	172	182	180	189	222	222	659	814	222	0.0
QoQ (%)	-4.4	7.0	8.9	5.7	-0.8	5.0	17.2	0.0	15.1	23.4		
Revenue (INR m)	12,233	13,250	14,531	15,685	15,389	16,585	19,712	20,243	55,699	71,929	19,980	1.3
YoY (%)	9.6	21.1	15.3	22.2	25.8	25.2	35.7	29.1	17.2	29.1	27.4	
GPM (%)	30.5	38.7	40.7	37.9	35.9	38.1	38.2	36.9	37.2	37.3	38.2	
SGA (%)	14.6	14.1	13.7	13.3	13.4	13.0	12.2	13.0	13.9	12.9	13.3	
EBITDA	1,939	3,252	3,922	3,865	3,461	4,151	5,112	4,847	12,979	17,570	4,975	-2.6
EBITDA Margin (%)	15.9	24.5	27.0	24.6	22.5	25.0	25.9	23.9	23.3	24.4	24.9	-100bp
EBIT	840	1,989	2,761	2,722	2,279	2,936	3,876	3,605	8,310	12,697	3,676	-1.9
EBIT Margin (%)	6.9	15.0	19.0	17.4	14.8	17.7	19.7	17.8	14.9	17.7	18.4	-60bp
Finance cost	374	297	302	298	274	250	247	221	1271	992	217	2.0
Other Income	244	-88	440	-34	99	582	84	248	562	1,013	200	24.0
ETR (%)	68.6	26.9	25.2	23.6	29.4	23.2	20.9	29.0	29.1	25.4	25.5	
Adj. PAT	1,447	1,636	2,626	2,398	1,997	3,010	3,230	3,069	8,106	11,306	3,265	-6.0
QoQ (%)	-12.4	13.1	60.5	-8.7	-16.7	50.8	7.3	-5.0			1.1	
YoY (%)	1.6	30.5	67.6	45.2	38.0	84.0	23.0	28.0	37.5	39.5	36.2	
Reported PAT	223	1,173	2,169	1,826	1,486	2,508	2,677	2,577	5,391	9,248	2,726	-5.5
Adj. EPS (INR)	0.3	0.3	0.6	0.5	0.4	0.6	0.7	0.7	1.8	2.4	0.7	-6.0

Key performance indicator

Y/E March	FY25				FY26			
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q
Revenue from Payers (INR mn)	10,901	11,824	12,976	14,075	13,597	14,682	17,821	18,381
YoY (%)	9.2	20.8	13.0	20.8	24.7	24.2	37.3	30.0
Contribution to Revenue (%)	89.1	89.2	89.3	89.7	88.4	88.5	90.4	90.4
Revenue from Providers (INR mn)	1,332	1,426	1,555	1,610	1,792	1,903	1,891	1,862
YoY (%)	13.3	23.7	38.6	36.4	34.5	33.5	21.6	20.6
Contribution to Revenue (%)	10.9	10.8	10.7	10.3	11.6	11.5	9.6	9.2
Full-Time Employees	35,858	38,380	39,595	39,409	39,917	44,185	48,522	46,860
Net Addition (QoQ)	814	2,522	1,215	(186)	508	4,268	4,337	(1,662)
Attrition	27.3	25.8	21.8	32.5	27.6	26.3	22.8	38.1
ACV (USD mn)	NA	NA	NA	NA	32	34	31	31

Our revised estimates

	Revised		Earlier		Change (%)	
	FY27E	FY28E	FY27E	FY28E	FY27E	FY28E
INR/USD	91.1	91.1	91.0	91.0		
Revenue (USD m)	907	1,031	926	1,056	-2.1%	-2.4%
Revenue (INR m)	82,634	93,976	84,273	96,085	-1.9%	-2.2%
EBIT (INR m)	14,765	17,253	14,862	17,491	-0.7%	-1.4%
EBIT margin(%)	17.9	18.4	17.6	18.2	30bps	20bps
PAT (INR m)	10,957	13,405	11,223	13,419	-2.4%	-0.1%
EPS (Rs)	2.3	2.9	2.4	2.9	-2.4%	-1.2%



Key highlights from the management commentary

- Organic growth remained robust at 15.0% CC in FY26 and 19.4% in 4QFY26, driven by strong expansion within existing clients, healthy demand across payer and provider operations, and growing contribution from newly added clients.
- Seasonal demand during the Medicare Advantage Annual Enrollment Period (AEP) and open enrollment cycle was significantly stronger than expected, contributing ~6% of FY26 revenue vs. ~3% historically, with BroadPath and clinical operations being key contributors.
- Commercial momentum remained healthy, with USD30.7m of potential steady-state ACV signed during 4QFY26 through expansion and new statements of work across 18 existing clients and clients added earlier during FY26. Full-year ACV wins were approximately USD130m.
- The company added 17 new clients during FY26, including several regional health plans and Blue Cross Blue Shield organizations, strengthening the future growth pipeline and improving diversification across the client portfolio.
- Client concentration continued to improve, with the top three clients now contributing less than 60% of revenue, while the number of clients generating more than USD20m annually increased to nine in FY26 from four in FY23.
- Payer verticals continued to dominate the revenue mix, contributing 89.7% of FY26 revenue, while the provider business contributed 10.3%, with management remaining optimistic on long-term provider-side opportunities in revenue cycle management (RCM).
- Management highlighted increasing traction in AI- and technology-led transformation offerings, particularly through the “Sagility Synchrony” suite and outcome-based managed services focused on cost reduction, member engagement, care management, and operational transformation for healthcare payers.
- The company emphasized that healthcare clients are increasingly seeking strategic partners capable of delivering measurable business outcomes and AI-enabled transformation rather than traditional manpower-based outsourcing services.
- Sagility continued to invest in AI and technological capabilities, with multiple AI-led pilots and operational deployments already implemented across healthcare workflows, while ensuring solutions remain explainable, auditable, compliant, and regulator-ready.
- The BroadPath acquisition strengthened Sagility’s capabilities in seasonal and member-facing operations, particularly during peak enrollment periods, while also expanding the company’s client access and US delivery capabilities.
- Management highlighted a strong pipeline of transformational opportunities, with ~USD575m worth of proposals currently submitted to clients, primarily centered around multi-year managed services and AI-led cost optimization engagements.
- The company reiterated that its growth strategy remains focused on expanding wallet share within existing accounts, increasing penetration into mid-market healthcare plans, and scaling transformational managed services offerings.
- Revenue visibility for FY27 remains strong, with management indicating that 7-8% growth is already embedded from existing contracts and prior deal wins, in addition to recurring seasonal revenue.

- Management guided for low double-digit CC revenue growth in FY27 and EBITDA margin at 24-25%, with margins expected to trend toward the upper end of the range if the current forex rates remain stable.
- Adjusted EBITDA margins for FY26 stood at 25.3%, exceeding earlier guidance despite the integration impact of BroadPath and increased investments in growth and delivery capabilities.
- 4Q EBITDA margins were impacted by a one-time employee bonus payout related to the transition of the salary hike cycle from a calendar-year basis to a financial-year basis, reducing quarterly margins by ~170bp.
- Management clarified that increasing onshore delivery exposure is largely driven by new clients and regulatory-sensitive engagements, while existing clients continue to prefer offshore delivery due to cost advantages.
- Operational efficiency remained a key focus area, with 4Q operating cash flow conversion at 104.6% supported by improved working capital management. DSO stood at 87 days, broadly stable sequentially despite accounting reclassification impacts.
- The company maintained a strong balance sheet, with a cash balance of INR9,038m at the end of FY26, providing flexibility for continued AI investments, inorganic growth opportunities, and debt repayment.
- Management reiterated its commitment to fully repay existing debt by the end of FY27 while preserving financial flexibility for strategic acquisitions focused on technology, AI capabilities, and client expansion opportunities.
- The company continues to evaluate both payer-side and provider-side acquisitions, with focus areas including technology-led capability enhancement, domain specialization, and client base expansion similar to the BroadPath acquisition.
- Industry conditions remain favorable for Sagility as healthcare payers continue to face profitability pressure from rising medical utilization, reimbursement challenges, and regulatory changes, increasing demand for cost takeout and operational efficiency initiatives.
- Management highlighted strong demand for Medicare Advantage-related services, including Star Ratings improvement programs, care management, member engagement, and AI-enabled administrative optimization solutions.
- The CMS ACCESS model and broader regulatory push toward outcome-based chronic care management align well with Sagility's strategy of combining healthcare expertise with AI-enabled care and operational transformation solutions.
- The company unveiled a significant brand evolution during the quarter, positioning Sagility as a healthcare-first, AI- and technology-led operations transformation partner focused on delivering measurable business outcomes through trusted collaboration and deep healthcare expertise.
- Sagility hosted its annual client summit with over 80 client participants, focusing on collaborative problem-solving around medical cost pressures, member experience enhancement, and AI adoption across healthcare operations.
- Employee headcount stood at 46,860 at the end of FY26 after seasonal ramp-downs following the enrollment season, while attrition increased modestly due to higher seasonal hiring activity during the year.

Financials and Valuation

Consolidated - Income Statement

	(INR m)					
Y/E March	FY23	FY24	FY25	FY26	FY27E	FY28E
Total Income from Operations	42,184	47,536	55,699	71,929	82,634	93,976
Change (%)		12.7	17.2	29.1	14.9	13.7
Employees Cost	24,942	29,376	34,989	45,103	51,861	58,950
Gross Profit	17,242	18,159	20,710	26,826	30,773	35,026
Margin (%)	40.9	38.2	37.2	37.3	37.2	37.3
Other Expenses	6,970	7,278	7,731	9,256	10,652	12,422
Total Expenditure	31,912	36,655	42,720	54,359	62,513	71,372
% of Sales	75.6	77.1	76.7	75.6	75.7	75.9
EBITDA	10,272	10,881	12,979	17,570	20,121	22,604
Margin (%)	24.4	22.9	23.3	24.4	24.3	24.1
Depreciation	6,443	6,892	4,669	4,874	5,357	5,351
EBIT	3,829	3,989	8,310	12,697	14,765	17,253
Margin (%)	9.1	8.4	14.9	17.7	17.9	18.4
Int. and Finance Charges	2,148	1,851	1,271	992	884	200
Other Income	177	279	563	1,013	826	940
PBT bef. EO Exp.	1,857	2,417	7,602	12,718	14,707	17,993
EO Items	0	0	0	-328	0	0
PBT after EO Exp.	1,857	2,417	7,602	12,389	14,707	17,993
Total Tax	421	134	2,211	3,141	3,750	4,588
Tax Rate (%)	22.7	5.6	29.1	25.4	25.5	25.5
Minority Interest	0	0	0	0	0	0
Reported PAT	1,436	2,283	5,391	9,248	10,957	13,405
Adjusted PAT	4,684	5,896	8,106	11,306	12,975	15,431
Change (%)		25.9	37.5	39.5	14.8	18.9
Margin (%)		12.4	14.6	15.7	15.7	16.4

Consolidated - Balance Sheet

	(INR m)					
	FY23	FY24	FY25	FY26	FY27E	FY28E
Total Income from Operations	42,184	47,536	55,699	71,929	82,634	93,976
Equity Share Capital	19,187	42,853	46,793	46,793	46,793	46,793
Total Reserves	42,880	21,578	36,568	49,798	59,659	71,723
Net Worth	62,067	64,431	83,361	96,591	1,06,452	1,18,516
Total Loans	23,237	16,647	5,670	0	0	0
Other Non-Current Liabilities	15,999	20,853	17,197	25,209	20,394	22,584
Deferred Tax Liabilities	4,602	4,710	4,279	4,211	4,211	4,211
Capital Employed	1,05,905	1,06,642	1,10,507	1,26,011	1,31,057	1,45,311
Gross Block	3,932	5,787	6,397	7,367	9,845	12,699
Less: Accum. Deprn.	977	1,955	2,698	3,099	5,035	7,195
Net Fixed Assets	2,955	3,832	3,699	4,268	4,810	5,504
CWIP	3	57	0	393	393	393
Right-of-use asset	5,295	5,665	5,521	4,868	6,523	6,984
Intangible assets	23,221	20,078	20,362	20,370	20,214	20,226
Goodwill	54,598	57,096	60,390	64,051	61,666	61,666
Other Non-Current Assets	1,899	2,714	2,326	2,615	2,644	2,674
Curr. Assets, Loans&Adv.	17,934	17,199	18,208	29,445	34,770	47,829
Account Receivables	6,376	7,400	8,637	18,390	11,208	14,821
Cash and Bank Balance	5,853	3,441	3,438	3,579	10,645	16,839
Other Current Assets	5,705	6,358	6,133	7,476	12,918	16,168
Curr. Liability & Prov.	10,564	14,521	10,891	18,975	14,160	16,350
Account Payables	2,135	2,593	2,136	2,217	3,054	5,114
Other Current Liabilities	7,702	11,255	7,803	15,396	9,743	9,874
Provisions	727	673	952	1,363	1,363	1,363
Net Current Assets	7,370	2,678	7,317	10,470	20,611	31,478
Misc Expenditure	0	0	0	0	0	0
Appl. of Funds	1,05,905	1,06,642	1,10,507	1,26,011	1,31,020	1,45,275

E: MOFSL Estimates

Financials and Valuation

Ratios						
Y/E March	FY23	FY24	FY25	FY26	FY27E	FY28E
Basic (INR)						
EPS	0.33	0.53	1.17	1.98	2.34	2.86
Cash EPS	2.60	2.98	2.73	3.40	3.92	4.44
BV/Share	14.5	15.0	17.8	20.6	22.7	25.3
DPS	0.0	0.0	0.0	0.0	0.2	0.3
Payout (%)	0.0	0.0	0.0	2.5	10.0	10.0
Valuation (x)						
P/E	128.4	80.8	36.8	21.8	18.4	15.0
Cash P/E	18.5	16.1	17.6	14.1	12.3	10.8
P/BV	3.0	2.9	2.4	2.1	1.9	1.7
EV/Sales	4.9	4.3	3.8	2.9	2.4	2.0
EV/EBITDA	20.2	19.0	16.3	11.9	9.7	8.4
Dividend Yield (%)	0.0	0.0	0.0	0.1	0.5	0.6
FCF per share	0.2	0.3	-0.5	-0.2	3.0	1.6
Return Ratios (%)						
RoE	2.8	3.6	7.3	10.3	10.8	11.9
RoCE	4.3	4.4	8.9	12.4	13.5	14.6
RoIC	3.7	4.7	7.0	10.1	11.3	13.0
Working Capital Ratios						
Fixed Asset Turnover (x)	15.0	14.0	14.8	18.1	18.3	18.2
Asset Turnover (x)	0.4	0.4	0.5	0.6	0.6	0.7
Debtor (Days)	53	53	53	52	51	51
Creditor (Days)	24	29	25	25	25	25
Leverage Ratio (x)						
Current Ratio	1.7	1.2	1.7	1.6	2.5	2.9
Interest Cover Ratio	1.8	2.2	6.5	12.8	16.7	86.3
Net Debt/Equity	0.4	0.2	0.2	0.0	0.0	0.0

Consolidated - Cash Flow Statement

Y/E March	FY23	FY24	FY25	FY26	FY27E	FY28E
PBIT	3,829	3,989	8,310	12,697	14,765	17,253
D&A	6,443	6,892	4,669	4,874	5,357	5,351
Working capital changes	26	-301	-4,470	-6,748	2,701	-4,673
Others	-983	-178	80	324	-28	-30
Operating cash flow	9,315	10,403	8,589	11,146	22,794	17,901
Taxes	-421	-134	-2,211	-3,141	-3,750	-4,588
Other Income	-1,972	-1,572	-708	21	-58	740
Cash flow before investing	6,922	8,696	5,670	8,026	18,986	14,053
Capex	-3,838	-5,050	-4,619	-5,189	-7,435	-6,517
Acquisitions	-2,415	-2,498	-3,294	-3,764	2,385	0
Free cash flow	669	1,148	-2,244	-927	13,937	7,535
Dividend Payment	0	0	0	-234	-1,096	-1,340
Equity raising	20,365	82	13,538	4,216	0	0
Debt raising/repayment	-18,919	-3,641	-11,298	-2,914	-5,776	0
Net cash flow	2,115	-2,412	-4	141	7,065	6,195
Opening Cash balance	3,738	5,853	3,441	3,438	3,579	10,645
Closing cash balance	5,853	3,441	3,438	3,579	10,645	16,839

E: MOFSL Estimates

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations). Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH00000412 and BSE enlistment no. 5028. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products and is a member of Association of Portfolio Managers in India (APMI) for distribution of PMS products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>. As per Regulatory requirements, Research Audit Report is uploaded on www.motilaloswal.com > MOFSL-Important Links > MOFSL Research Analyst Compliance Audit Report.

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH00000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL .

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani
Email: nainesh.rajani@motilaloswal.com
Contact: (+65) 8328 0276

Specific Disclosures

- Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies). MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.
Nature of Financial interest is holding equity shares or derivatives of the subject company
- Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report:No
- Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
- Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as an officer, director or employee of subject company(ies).
- MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
- MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

- financial interest in the subject company
 - actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
 - received compensation/other benefits from the subject company in the past 12 months
 - any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
 - acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
 - be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
 - received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
 - Served subject company as its clients during twelve months preceding the date of distribution of the research report.
- The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report
 Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI, enlistment as RA with Exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com.

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com
Mr. Neeraj Agarwal	022 40548085	na@motilaloswal.com
Mr. Siddhartha Khemka	022 50362452	po.research@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412, BSE enlistment no. 5028, AMFI registered Mutual Fund Distributor and SIF Distributor: ARN : 146822. IRDA Corporate Agent – CA0579, APMI: APRN00233. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.